YIH
RNA

Y-Intercept (HK)’s Atrium Therapeutics RNA Stock Holding History

Y-Intercept (HK)’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$472K Buy
+35,103
New +$459K 0.01% 1330

Other funds holding RNA

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Y-Intercept (HK)'s RNA Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 35,103 shares worth $472K. The stake represents 0.01% of the portfolio and ranks #1330 among its holdings.

8 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Y-Intercept (HK) held 35,103 shares of Atrium Therapeutics worth $472K as of Q2 2026.
  • Atrium Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
  • Atrium Therapeutics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1330 holding.
  • 8 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.